Q: Please comment on earnings and guidance for these 2 companies. Thank you.
5i Research Answer:
OLY does not report until Friday (estimated date).
TARS reported a loss of 60c per share, beating estimates of a loss of 74c. Revenue of $66.4M beat estimates of $58.3M. EBITDA of -$24M beat estimates by 23%. Xdemvy sales were strong and contributed to the beat. Revenue was up 5-fold with the launch of products. Net cash is $240M. Still losing money, it is expected to be profitable ($1.12 per share) in 2026. We would consider it high risk due to its size and sector. The stock has been weak, down 22% this year and we would not give it a strong endorsement in this market.